Current perspectives in cannabis use disorder

Margaret HANEY - New York - USA

Changing attitudes and laws regarding the use of cannabis has been associated with a marked increase
in both the prevalence of cannabis use and the development of cannabis use disorders (CUD) in the
United States. Currently, approximately 24% of patients entering treatment for substance use in the US
have a diagnosis of cannabis use disorder, yet their treatment outcome is poor, with the vast majority of
patients failing to achieve continued abstinence. A major limitation of existing treatment options is the lack
of FDA-approved medications to facilitate treatment of this disorder. The objective of this presentation is
to describe the current state of the field in terms of medications development for CUD: How potential
treatment medications influence cannabis intoxication, withdrawal and self-administration in the human
laboratory, what medications have been tested in randomized controlled clinical trials, and what is on the
horizon.